Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 in Obstructive Sleep Apnea and Obesity
NCT07787260Phase 3Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 3 trial of poterepatide in obstructive sleep apnea (OSA), obesity, sponsored by Huadong Medicine. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
poterepatide
03
Conditions
obstructive sleep apnea (OSA)obesity
Beyond the preview
Go deeper on NCT07787260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787260.